Retrograde Transvenous Neuroperfusion: A Back Door Treatment for Stroke | Zendy

John G. Frazee | Zendy; Xia Luo | Zendy; Guoming Luan | Zendy; David S. Hinton | Zendy; David A. Hovda | Zendy; Mark S. Shiroishi | Zendy; Larry T. Barcliff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Retrograde Transvenous Neuroperfusion: A Back Door Treatment for Stroke

Author(s) -

John G. Frazee,

Xia Luo,

Guoming Luan,

David S. Hinton,

David A. Hovda,

Mark S. Shiroishi,

Larry T. Barcliff

Publication year - 1998

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.29.9.1912

Subject(s) - medicine , stroke (engine) , anesthesia , infarction , ischemia , pathophysiology , thrombolysis , tissue plasminogen activator , isoflurane , central nervous system disease , surgery , cardiology , myocardial infarction , mechanical engineering , engineering

Stroke is the third leading cause of death and the leading cause of adult disability in the United States. The clot-lysis drug tissue plasminogen activator is the only treatment that has been effective for acute stroke patients, yet there are significant limitations to its use and effectiveness. In this study retrograde transvenous neuroperfusion (RTN) was evaluated for its efficacy in reversing acute ischemia, preventing paralysis, and limiting pathological evidence of infarction in baboons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research